<code id='9B71B3100E'></code><style id='9B71B3100E'></style>
    • <acronym id='9B71B3100E'></acronym>
      <center id='9B71B3100E'><center id='9B71B3100E'><tfoot id='9B71B3100E'></tfoot></center><abbr id='9B71B3100E'><dir id='9B71B3100E'><tfoot id='9B71B3100E'></tfoot><noframes id='9B71B3100E'>

    • <optgroup id='9B71B3100E'><strike id='9B71B3100E'><sup id='9B71B3100E'></sup></strike><code id='9B71B3100E'></code></optgroup>
        1. <b id='9B71B3100E'><label id='9B71B3100E'><select id='9B71B3100E'><dt id='9B71B3100E'><span id='9B71B3100E'></span></dt></select></label></b><u id='9B71B3100E'></u>
          <i id='9B71B3100E'><strike id='9B71B3100E'><tt id='9B71B3100E'><pre id='9B71B3100E'></pre></tt></strike></i>

          
          WSS
          Boston Scientific headquarters -- Health coverage from STAT
          Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

          Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

          It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

          advertisement

          Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          Wikipedia